To the full analysis
Buyback calculator for Zenas BioPharma
Zenas BioPharma stock: key metrics
ZBIOZenas BioPharma had an operating margin of −2,113.9% and a return on invested capital (ROIC) of −52.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2022 | no data | no data | no data |
| 2023 | 100.0% | −74.3% | −74.2% |
| 2024 | −2,682.8% | −3,277.8% | −3,139.8% |
| 2025 | 100.0% | −2,113.9% | −3,777.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2022 | 62.0% | no data | −100.0% |
| 2023 | 16.4% | −62.7% | −54.4% |
| 2024 | −50.2% | −72.4% | −42.4% |
| 2025 | −100.0% | −52.6% | −98.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 19 Sep 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.